84.42

2.09% -1.80

After Hours: 85.92 1.50 +1.78%

Liquidia Corp (LQDA)

Overview News Price History Option Chain Financials Discussions Forecast

Liquidia Corp stock is traded at $84.42, with a volume of 1.45M. It is down -2.09% in the last 24 hours and up +8.00% over the past month. Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Previous Close:

$86.22

Open:

$86.22

24h Volume:

1.45M

Relative Volume:

0.77

Market Cap:

$7.51B

Revenue:

$288.07M

Net Income/Loss:

$22.31M

P/E Ratio:

596.19

EPS:

0.1416

Net Cash Flow:

$41.15M

1W Performance:

+9.52%

1M Performance:

+8.00%

6M Performance:

+98.75%

1Y Performance:

+330.71%

1-Day Range:

$83.63

$89.72

1-Week Range:

$77.78

$91.10

52-Week Range:

$16.82

$91.10

Liquidia Corp Stock (LQDA) Company Profile

Name

Liquidia Corp

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

919.328.4400

Address

419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC

Employee

216

Twitter

@Liquidia_Inc

Next Earnings Date

2026-08-11

Latest SEC Filings

LQDA's Discussions on Twitter

Compare LQDA vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LQDA Liquidia Corp	84.42	7.67B	288.07M	22.31M	41.15M	0.1416
TAK Takeda Pharmaceutical Co Adr	17.44	55.06B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.94	43.07B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.08	35.88B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.92	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	527.94	26.32B	3.17B	1.29B	1.01B	27.09

Liquidia Corp Stock (LQDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Aug-15-25	Resumed	Jefferies	Buy
May-19-25	Downgrade	Oppenheimer	Perform → Underperform
Dec-20-24	Initiated	Wells Fargo	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy
Sep-19-22	Resumed	Wedbush	Underperform
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform
Jul-22-22	Initiated	Ladenburg Thalmann	Buy
May-31-22	Initiated	BTIG Research	Buy
May-26-22	Initiated	BofA Securities	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform
Aug-20-18	Initiated	Jefferies	Buy
Aug-20-18	Initiated	Needham	Buy

View All

Liquidia Corp Stock (LQDA) Latest News

Jul 27, 2026